Trial Profile
Nivolumab Plus Erlotinib in Patient with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 05 Jun 2018 New trial record
- 23 May 2018 Results published in the Journal of Thoracic Oncology